[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-365700-105":59,"doc-detail-365700-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","spatiotemporal-study-of-a-risk-stratification-epigenetic-based-biomarker-assay-in-patients-with-barrett-esophagus-research-report","Spatiotemporal Study of a Risk-Stratification Epigenetic-Based Biomarker Assay in Patients With Barrett Esophagus - Research Report","","Barrett esophagus (BE) is a key risk factor for esophageal adenocarcinoma (EAC), and accurate risk stratification is crucial for guiding surveillance. The study evaluates Esopredict, a validated methylation-based biomarker assay, by measuring spatiotemporal performance across multiple sampling points. Researchers profiled 220 biopsies from 58 BE patients, including spatial and temporal cohorts, and compared progression outcomes using 5-year risk scores. Results show high sensitivity, supporting robust clinical use in distinguishing high- from low-risk BE patients.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/spatiotemporal-study-of-a-risk-stratification-epigenetic-based-biomarker-assay-in-patients-with-barrett-esophagus-research-report/365700/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/spatiotemporal-study-of-a-risk-stratification-epigenetic-based-biomarker-assay-in-patients-with-barrett-esophagus-research-report/365700.png","ImageObject",300,407,{"name":92,"@type":93},"Alex Sinclair","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":14},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the purpose of Esopredict in this study?","Question",{"text":112,"@type":113},"Esopredict is used to compute a progression risk score for BE patients, quantifying the likelihood of future progression to high-grade dysplasia or EAC within 5 years.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were biopsies sampled and analyzed?",{"text":117,"@type":113},"The study profiled 220 biopsies from 58 BE patients, including spatial sampling (multiple anatomic locations in one endoscopy) and temporal sampling (multiple endoscopies at different time points).",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main sensitivity findings?",{"text":121,"@type":113},"For spatially profiled patients, sensitivity reached 81% overall and increased to 100% when endpoint biopsies occurred within 5 years. For temporally profiled patients, sensitivity was 100% based on the biopsy closest to the endpoint.",{"name":123,"@type":110,"acceptedAnswer":124},"How do the results support clinical decision-making?",{"text":125,"@type":113},"The findings support using Esopredict to identify high-risk BE patients who may benefit from endoscopic eradication therapy or more frequent surveillance, while low-risk patients may be suitable for less frequent monitoring and noninterventional observation.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},365700,1792226002,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":14,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","ARTICLE 1285  \nINTRODUCTION: Barrett esophagus (BE) is the strongest known risk factor for developing esophageal adenocarcinoma (EAC), the second-most lethal cancer in the United States. Esopredict is a novel validated methylationbased biomarker assay that provides precise quantification of neoplastic progression risk in BE patients. Inherit challenges, including tissue heterogeneity, sampling error, interobserver variability, and inconsistent adherence to surveillance biopsy guidelines, may affect the predictive value results of Esopredict obtained at different anatomic locations or different sampling time points.  \nSpatiotemporal Study of a Risk-Stratification Epigenetic-Based Biomarker Assay in Patients With Barrett Esophagus  \nSarah E. Laun, PhD1, Lisa Kann, PhD1, Jerome Braun, PhD 1, Francia Pierre, MPH1, Suji Kim, BS1, Stacey Gilbert, MBA, MPH1 , Daniel Lunz, MBA1, Andrew Kalra, MD2 ,3, Ke Ma, MD2 ,4, Yulan Cheng, PhD2, Cadman L. Leggett, MD5, Ali H. Zaidi, MD6 ,  \nAshten N. Omstead, MD6, Louis Korman, MD7, Blair Jobe, MD6 ,8, Lorrie Perpetua, MD9, Bruce D. Greenwald, MD10, Tara Maddala, PhD 1 and Stephen J. Meltzer, MD2 , 11  \nESOPHAGUS  \n1Previse, Baltimore, Maryland, USA; 2 Department of Medicine, Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; 3Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA; 4 Department of Medicine, Division of Gastroenterology and Hepatology, Jefferson Einstein Philadelphia Hospital, Philadelphia, Pennsylvania, USA; 5Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA; 6Allegheny Health Network Cancer Institute, Allegheny Health Network, Pittsburgh, Pennsylvania, USA; 7Capital Digestive Care, Chevy Chase, Maryland, USA; 8Department of Surgery, Esophageal Institute, Allegheny Health Network, Pittsburg, Pennsylvania, USA; 9Research Tissue Biorepository Core Facility, University of Connecticut, Storrs, Connecticut, USA; 10 Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland, USA; 11Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Correspondence: Stephen J. Meltzer, MD. E-mail: [smeltzer@jhmi.edu](smeltzer@jhmi.edu).  \nReceived August 16, 2024; accepted January 24, 2025; published online February 12, 2025  \nCopyright © 2025 The Author(s) . Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology The American Journal of GASTROENTEROLOGY  \nESOPHAGUS  \nMETHODS: To investigate thespatiotemporal performance of Esopredict across multiplespatiotemporal sampling points, we profiled 220 biopsies obtained from 58 BE patients, including 11 patients with overlapping spatial and temporal biopsies. We focused on spatial profiling (i.e., multiple biopsies obtained at several anatomic locations during a single endoscopy)and temporal profiling(i.e., biopsies obtained from multiple endoscopies performed at different time points). Each patient had an initial histologic diagnosis of nondysplastic Barrett esophagus, indefinite for dysplasia, or low-grade dysplasia. Final follow-up (endpoint) biopsies showed either high-grade dysplasia orEAC(progressors), or nondysplastic Barrett esophagus, indefinite for dysplasia, or lowgrade dysplasia(nonprogressors). Biopsies were analyzed with Esopredict to compute a progression risk score, which quantified the likelihood of future progression to high-grade dysplasia or EAC within 5 years.  \nRESULTS: In 52 spatially profiled patients, Esopredict demonstrated a sensitivity of 81%(17/21 progressor patients), based on the highest-scoring biopsyfrom each patient;sensitivity increasedto100%(12/12)when endpoint biopsies occurredwithin5years of the index(initial)biopsy. In28temporally profiled patients, sensitivity was 100%(8/8 patients), based on the biopsy performed at","cbCaicfAfFThAPqV","https://ap.wps.com/l/cbCaicfAfFThAPqV","pdf",1020927,11,"English","# Introduction\n# Methods\n# Results\n# Discussion\n# Keywords","[{\"question\":\"What is the purpose of Esopredict in this study?\",\"answer\":\"Esopredict is used to compute a progression risk score for BE patients, quantifying the likelihood of future progression to high-grade dysplasia or EAC within 5 years.\"},{\"question\":\"How were biopsies sampled and analyzed?\",\"answer\":\"The study profiled 220 biopsies from 58 BE patients, including spatial sampling (multiple anatomic locations in one endoscopy) and temporal sampling (multiple endoscopies at different time points).\"},{\"question\":\"What were the main sensitivity findings?\",\"answer\":\"For spatially profiled patients, sensitivity reached 81% overall and increased to 100% when endpoint biopsies occurred within 5 years. For temporally profiled patients, sensitivity was 100% based on the biopsy closest to the endpoint.\"},{\"question\":\"How do the results support clinical decision-making?\",\"answer\":\"The findings support using Esopredict to identify high-risk BE patients who may benefit from endoscopic eradication therapy or more frequent surveillance, while low-risk patients may be suitable for less frequent monitoring and noninterventional observation.\"}]","Spatiotemporal Study of a Risk-Stratification Epigenetic-Based Biomarker Assay in Patients With Barrett Esophagus - Research Report | PDF",1790161866,28,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3c9ccbbe2820304840d53391e1d45ea8.webp",983,1296,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/88e640bb1326ebf595967d6a8fd8618f.webp",982,1294,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f7823485c0e6c5dd9413c956d801ed2.webp",981,1293,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/93696f027978861ac7420e0b2a31d28b.webp",980,1292]